<DOC>
	<DOCNO>NCT01535261</DOCNO>
	<brief_summary>The present study provide additional efficacy safety data 0.5-mg ranibizumab use need ( PRN ) dose 24 month patient visual impairment due macular edema secondary Central Retinal Vein Occlusion ( CRVO ) . Spectral domain high-definition optical coherence tomography ( OCT ) image analyze gain insight predictive factor disease progression possibility reduce monitoring assessed Year 2 . The result open-label study provide long-term safety efficacy data guide recommendation use ranibizumab indication .</brief_summary>
	<brief_title>Ranibizumab Intravitreal Injections Patients With Visual Impairment Due Macular Edema Secondary Central Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female patient ≥ 18 year age Diagnosis visual impairment exclusively due ME secondary CRVO BCVA score Screening Baseline 73 19 letter Early Treatment Diabetic Retinopathy Study ( ETDRS ) , inclusively ( approximate Snellen chart equivalent 20/40 20/400 ) Uncontrolled blood pressure define systolic value &gt; 160 mm Hg diastolic value &gt; 100 mm Hg Screening Baseline . Any active periocular ocular infection inflammation Screening Baseline either eye Uncontrolled glaucoma Screening Baseline diagnose within 6 month Baseline either eye Use systemic antivascular endothelial growth factor ( antiVEGF ) drug within 6 month Baseline ( eg , sorafenib [ Nexavar® ] , sunitinib [ Sutent® ] , bevacizumab [ Avastin® ] )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ophthalmology</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Central Retinal Vein Occlusion</keyword>
</DOC>